Physician profile
William Lyle
NPI 1700851037
$4,109.28
in general payments reported to CMS, 2019-2025
15 companies · $75.00 in 2025
The $75.00 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $305 · 2021: $766 · 2022: $332 · 2023: $1,111 · 2024: $371 · 2025: $75.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,556.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,328.09 | 2019-2022 | |
| Abbvie INC. | $613.66 | 2023-2024 | |
| Mentor Worldwide LLC | $416.45 | 2019-2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Tepha INC | $404.53 | 2019-2020 | |
| Sientra, INC. | $339.68 | 2020-2021 | |
| Galderma Laboratories, L.P. | $227.68 | 2019-2024 | Dysport |
| Integra Lifesciences Corporation | $206.70 | 2020-2024 | Durasorb Monofilament Mesh, Integra, Surgimend |
| Solta Medical, A Division of Bausch Health US, LLC | $164.52 | 2019-2024 | |
| Tela Bio, INC. | $136.36 | 2023-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Apyx Medical Corporation | $80.96 | 2019 | |
| Motiva USA, LLC | $75.00 | 2025 | |
| Acelrx Pharmaceuticals, INC. | $50.12 | 2021-2022 | |
| Merz North America, INC. | $34.73 | 2021 | |
| Medtronic, INC. | $15.88 | 2022 | |
| Smith+Nephew, INC. | $14.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Lyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.